<DOC>
	<DOCNO>NCT02774785</DOCNO>
	<brief_summary>The new device look call MarginProbe . It disposable probe measure margin tissue remove check clear cancer cell , breast conservation surgery . After specimen radiology , allow Surgeon remove tissue necessary , operation involve margin identify . This minimise need repeat operation . Previous study carry elsewhere world ( USA Israel ) identify probe reduces re-excision rate never study UK . The trial involve randomly allocate patient theatre , either MarginProbe procedure breast conserving surgery radiology complete , .</brief_summary>
	<brief_title>Does Intra-operative MarginProbe Use Reduce Re-excision Rates ?</brief_title>
	<detailed_description>Almost 60 % patient diagnose breast cancer ( 48000 annually UK ) undergo breast conserving surgery ( BCS . Surgical removal cancer aim reduce risk local recurrence patient mortality . In order minimise amount tissue remove , excision cancer-free area ( margin ) undertaken . Further surgery , follow initial breast cancer surgery , require 25 % - 30 % patient disease find edge tissue remove . Reducing need operation benefit patient ( reduce number operation require , improve cosmetic outcome minimise anxiety ) NHS ( realise economic benefit ) . MarginProbe , disposable probe measure margin tissue remove breast cancer surgery , allow surgeon remove tissue surgical procedure clear involved margin , minimise subsequent re-operations . Four hundred sixty patient 6 specialist Breast Units randomly allocate BCS ( specimen radiology ) , telephone randomisation , either : - MarginProbe assessment surgical specimen re-excision margin require ; - Standard BCS ( clinical radiological clear margin ) whereby wound close surgery complete ( standard UK practice ) .</detailed_description>
	<criteria>Inclusion Criteria ; Women age 1890 year DCIS Invasive Breast cancer contain DCIS diagnose histopathologically . Histologically diagnose DCIS invasive lobular cancer core biopsy ( B5a B5b ) . Tumour size 1.5cm 4cm undergoing breast cancer surgery . Written informed consent . Exclusion Criteria ; Unsuitable BCS basis tumour size ( &lt; 1.5cm &gt; 4cm ) stage . Radiotherapy contraindicate . No histopathological evidence DCIS invasive lobular cancer . Neoadjuvant chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>